Occam Places Dan Kemp as CEO of Shinobi Therapeutics
Shinobi Therapeutics, a newly formed iPS cell therapy company created through the merger of Thyas Ltd (Japan) and Evade Biotechnology (USA) has appointed Dan Kemp as CEO. Founded on the basis of highly innovative iPSC and immune evasion research out of the University of Kyoto and UCSF, the enterprise was funded by key investors including F-Prime Capital and Eight Roads.
Previously, Dan served as CEO of Wugen Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic, off-the-shelf cell therapies. Prior to Wugen, Dan held a variety of senior Business Development and R&D leadership roles with Takeda and Novartis.
Dan received his BSc and Ph.D. in molecular pharmacology from the University of Kent (UK).
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.